{"orpha":90052,"name":"Recurrent hepatitis C virus induced liver disease in liver transplant recipients","type":"Particular clinical situation in a disease or syndrome","group":"Disorder","status":"active","flags":[],"synonyms":[],"definition":"A rare hepatic disease characterized by recurrence of hepatitis C virus infection after liver transplantation, leading to liver injury with features resembling those observed in the non-transplant graft, and typically developing after three months post-transplantation. The clinical course is highly variable, although patients most commonly develop progressive chronic liver disease with higher viral loads and more rapid fibrosis progression than in the immunocompetent population.","note":null,"url":"https://raremap.alftech.space/d/ORPHA-90052/","orphanet_url":"https://www.orpha.net/en/disease/detail/90052","names":{"fr":{"name":"Manifestations hépatiques récurrentes causées par le virus de l'hépatite C chez les transplantés hépatiques","definition":"Maladie hépatique rare caractérisée par la récidive de l'infection par le virus de l'hépatite C après transplantation hépatique, entraînant une atteinte hépatite dont les signes ressemblent à ceux observés chez les non transplantés et se développant généralement trois mois après la transplantation. L'évolution clinique est très variable, bien que les patients développent le plus souvent une maladie hépatique chronique progressive avec une charge virale plus élevée et une progression plus rapide de la fibrose que dans la population immunocompétente."},"de":{"name":"Rekurrente Hepatitis-C-Virus-induzierte Lebererkrankung bei Lebertransplantierten","definition":"Eine seltene Lebererkrankung, die durch eine erneute Infektion mit dem Hepatitis-C-Virus nach einer Lebertransplantation gekennzeichnet ist und zu einer Leberschädigung führt, die den Merkmalen des nicht transplantierten Transplantats ähnelt und sich typischerweise nach drei Monaten nach der Transplantation entwickelt. Der klinische Verlauf ist sehr unterschiedlich, obwohl die Patienten am häufigsten eine progressive chronische Lebererkrankung mit höherer Viruslast und schnellerer Fibroseprogression als in der immunkompetenten Bevölkerung entwickeln."},"es":{"name":"Enfermedad hepática por recurrencia del virus de la hepatitis C en trasplantados hepáticos","definition":"Es una enfermedad hepática poco frecuente caracterizada por la reaparición de la infección por el virus de la hepatitis C tras el trasplante de hígado, lo que provoca una lesión hepática con características similares a las observadas en el injerto no trasplantado, y que suele desarrollarse después de tres meses post-trasplante. El curso clínico es muy variable, aunque lo más habitual es que los pacientes desarrollen una enfermedad hepática crónica progresiva con cargas virales más elevadas y una progresión de la fibrosis más rápida que en la población inmunocompetente."},"it":{"name":"Epatiti ricorrenti da virus dell'epatite C nei pazienti trapiantati di fegato","definition":"Si tratta di un'epatopatia rara, caratterizzata da infezioni ricorrenti da virus dell'epatite C dopo il trapianto di fegato, che causano lesioni epatiche con caratteristiche simili a quelle osservate nell'innesto, e che in genere si sviluppano tre mesi dopo il trapianto. Il decorso clinico è molto variabile, anche se i pazienti di solito sviluppano un'epatopatia cronica progressiva con cariche virali più elevate e una progressione della fibrosi più rapida rispetto alla popolazione immunocompetente."},"nl":{"name":"Terugkerende hepatitis C-virus-geïnduceerde leverziekte bij levertransplantaatrecipiënten","definition":"Een zeldzame aandoening van lever, gekenmerkt door recidiverende infectie door hepatitis C-virus na levertransplantatie, resulterend in letsel van lever met kenmerken gelijkaardig aan de kenmerken die bij niet-getransplanteerd weefsel worden waargenomen, en doorgaans met een aanvang na drie maanden na transplantatie. Het klinische verloop is zeer variabel, maar meestal ontwikkelen patiënten progressieve chronische leverziekte met hogere virale lading en snellere progressie van fibrose in vergelijking met de immuuncompetente populatie."},"pt":{"name":"Doença hepática recorrente induzida pelo vírus da Hepatite C em recetores de transplante hepático"},"pl":{"name":"Nawracające zapalenie wątroby typu C indukujące chorobę wątroby u biorców przeszczepionej wątroby"},"cs":{"name":"Rekurentní postižení jater indukované virem hepatitidy C u příjemců transplantátu"},"uk":{"name":"Рецидивуючі захворювання печінки, спричинені вірусом гепатиту С, у реципієнтів трансплантації печінки","definition":"A rare hepatic disease characterized by recurrence of hepatitis C virus infection after liver transplantation, leading to liver injury with features resembling those observed in the non-transplant graft, and typically developing after three months post-transplantation. The clinical course is highly variable, although patients most commonly develop progressive chronic liver disease with higher viral loads and more rapid fibrosis progression than in the immunocompetent population."},"zh":{"name":"复发性丙型肝炎病毒所致肝移植受者肝病"},"tr":{"name":"Karaciğer nakli alıcılarında tekrarlayan hepatit C virüsünün neden olduğu karaciğer hastalığı"}},"xrefs":[{"source":"ICD-10","code":"B18.2","qualifier":"NTBT","icd_relation":"attributed","validated":true},{"source":"ICD-11","code":"1E51.1","qualifier":"NTBT","icd_relation":"attributed","validated":true},{"source":"UMLS","code":"C5681349","qualifier":"E","icd_relation":null,"validated":true}],"associations":[],"incoming_associations":[],"preferential_parent":{"orpha":57146,"name":"Rare hepatic disease"},"parents":[{"orpha":565779,"name":"Rare disorder potentially indicated for transplant or complication after transplantation","classifications":[233]},{"orpha":57146,"name":"Rare hepatic disease","classifications":[183]}],"children":[],"genes":[],"genes_via_subtypes":[],"inheritance":["Not applicable"],"onset":["All ages"],"prevalence":[{"type":"Point prevalence","qualification":"Value and class","class":"1-9 / 100 000","value":7.0,"area":"Europe","status":"Validated","source":"European Medicines Agency[OTHER]"}],"phenotypes":null}